Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | TOURMALINE-AL1: ixazomib-dexamethasone for AL amyloidosis

Ashutosh Wechalekar, MBBS, FRCP, FRCPath, University College London Hospitals NHS Trust, London, UK, discusses findings from the Phase III TOURMALINE-AL1 study (NCT01659658), evaluating ixazomib and dexamethasone in the treatment of amyloid light-chain (AL) amyloidosis. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).